MEK and MET Inhibition in Colorectal Cancer

NCT02510001

Last updated date
Study Location
Oxford University Hospital NHS Trust
Oxford, , OX3 7LE, United Kingdom
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Solid Tumor, Colorectal Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

for the completed initial dose escalation phase using PF-02341066/PD-0325901 are listed in Appendix 7.) All patients

- Age ≥ 16 years (>18 years in France)

- ECOG performance status 0-1 (Appendix 1)

- Adequate respiratory function on clinical assessment

- Left ventricular ejection fraction (LVEF) ≥ 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram┼

- Able to give informed consent prior to any screening procedures being performed and be capable of complying with the protocol and its requirements

- Haematological and biochemical indices within the ranges shown below:

- Haemoglobin (Hb) ≥ 9g/dl (transfusion to achieve this allowed ),

- Neutrophils ≥ 1,500/μl,

- Platelet count ≥ 100,000/μl,

- AST or ALT ≤ 2.5 x ULN, patient with liver metastases ≤ 5 × ULN,

- Alkaline phosphatase ≤ 5 x ULN,

- Serum Bilirubin ≤ 1.5 x ULN,

- Creatinine Clearance ≥ 50ml/min (Calculated by Cockcroft Gault equation, or by EDTA) (Appendix 2)

- Able to swallow oral medication

- Life expectancy of at least 3 months.

Dose escalation phase:

- Patients with any advanced solid tumours

- Patients for whom the combination of PF-02341066 with Binimetinib is a reasonable option.

Dose expansion phase:

Patients will be eligible for pre-screening for this phase provided that:

- They have given informed consent to screening.

- They are willing to undergo a biopsy for assessment of tumour RAS mutation status and c-MET assessment.

- The Investigator anticipates that they are likely to satisfy the eligibility criteria for the trial. Formal screening should not be performed until the tumour pre-screening result is known.

Eligibility for the trial, in patients passing pre-screening, requires:

- Histologically confirmed colorectal adenocarcinoma that is either a) RASMT (KRAS codon 12, 13, 61, 117, 146; NRAS codon 12, 13, 61, 117, 146) or b) RASWT/c-MET mutated/amplified or c) RASWT/c-MET over-expressed with progressive disease on or within 6 months of completion of adjuvant therapy or after chemotherapy and/or targeted therapies for metastatic disease.

- Prior treatment with an EGFR targeted monoclonal antibody for patients with RASWT/c-MET mutated or amplified CRC or c) RASWT/c-MET over-expressed CRC.

- No evidence for a mutation in BRAF at codon600

- Metastases accessible for biopsy on 2-3 occasions

- At least one other measurable lesion (according to RECIST v1.1).

- Unsuitable for potential curative resection. ┼For non-UK territories: if echocardiogram (ECHO) cannot be performed, a MUGA scan may be performed in compliance with local policy, applicable national legislation and relevant approvals. Cardiac ejection fraction must be determined as measured by ECHO in the UK.

EXCLUSION CRITERIA (

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

for the completed initial dose escalation phase
using PF-02341066/PD-0325901 are listed in Appendix 7.) All patients


- Unstable ischaemic heart disease, cardiac dysrhythmias, coronary/peripheral artery
bypass graft or cerebrovascular accident within 6 months prior to starting treatment.


- Uncontrolled arterial hypertension despite medical treatment.


- Ongoing congestive heart failure or cardiac dysrhythmias of NCI CTCAE Grade ≥2 or
uncontrolled atrial fibrillation.


- History of extensive disseminated/bilateral or known presence of Grade 3 or 4
interstitial fibrosis or interstitial lung disease, including a history of
pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung
disease (ILD), obliterative bronchiolitis, and pulmonary fibrosis. A history of prior
radiation pneumonitis is allowed.


- Any active central nervous system (CNS) lesion (i.e., those with radiographically
unstable, symptomatic lesions) and/or leptomeningeal metastases. However, patients
treated with stereotactic radiotherapy or surgery are eligible if the patient remained
without evidence of CNS disease progression ≥ 3 months. Patients must be off
corticosteroid therapy for ≥ 3 weeks.


- Patients who have neuromuscular disorders that are associated with elevated CK (e.g.,
inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal
muscular atrophy);


- Patients who are planning on embarking on a new strenuous exercise regimen after first
dose of study treatment. NB: Muscular activities, such as strenuous exercise, that can
result in significant increases in plasma CK levels should be avoided while on
Binimetinib treatment


- Spinal cord compression unless treated with the patient attaining good pain control
and stable or recovered neurologic function.


- Carcinomatous meningitis or leptomeningeal disease.


- History of hypoalbuminaemia, or patients with peritoneal disease or pleural disease,
where there is a requirement for ascitic or pleural taps.


- History of retinal vein occlusion, intraocular pressure > 21 mmHg or patient
considered at risk of retinal vein thrombosis (e.g. history of hyperviscosity or
hypercoagulability syndromes).


- History of retinal degenerative disease.


- History of Gilbert's syndrome.


- Active infections (including chronic hepatitis type B or C and HIV infection if status
known), severe immunologic defect, compromised bone marrow function.


- Other severe acute or chronic medical (including severe gastro-intestinal disorders
e.g. partial bowel obstruction, malabsorption, active inflammatory bowel disease) or
psychiatric conditions or laboratory abnormalities that the investigator considers
would make the patient a poor trial candidate, would impart excess risk associated
with study participation or drug administration or could interfere with protocol
compliance or the interpretation of trial results.


- Patients who have undergone major surgery ≤ 3 weeks prior to starting study drug or
who have not recovered from side effects of such procedure.


- Use of drugs or foods that are known potent CYP3A4 inhibitors or inhibitors or are
CYP3A4 substrates with narrow therapeutic indices (see Appendix 5).


- Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or
chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C)
and four weeks for investigational medicinal products before treatment. Patients with
prostate cancer may continue to receive endocrine therapy to maintain castrate levels
of androgens.


- Resting ECG with QTc > 480msec at 2 or more time points within a 24h period (using
Fredericia correction).


- Requirement for medication known to prolong QT interval (Appendix 5).


- History of other malignancy less than 3 years before the diagnosis of current cancer,
EXCLUDING the following: Non-melanoma skin cancer, in situ carcinoma of the cervix
treated surgically with curative intent, other malignant tumours that have been
treated curatively and patient is deemed disease-free


- Women with the ability to become pregnant (or already pregnant or lactating). However,
those female patients who have a negative serum pregnancy test before enrolment and
agree to use one highly effective form of contraception (oral, injected or implanted
hormonal contraception or intra-uterine device) in addition to condom plus spermicide
for four weeks before entering the trial, during the trial and for six months
afterwards are considered eligible.


- Male patients with partners of child-bearing potential unless they agree to take
measures not to father children by using one form of highly effective contraception
including oral, injected or implanted hormonal contraception or intra-uterine device
in addition to condom plus spermicide, during the trial and for six months
afterwards). Men with pregnant or lactating partners should be advised to use barrier
method contraception (condom plus spermicidal gel) to prevent exposure to the foetus
or neonate.


- Prior exposure to any of a HGF, cMET or a MEK inhibitor.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Solid Tumor, Colorectal CancerMEK and MET Inhibition in Colorectal Cancer
NCT02510001
  1. Oxford,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE MEK and MET Inhibition in Colorectal Cancer
Official Title  ICMJE A Sequential Phase I Study of MEK1/2 Inhibitors PD-0325901 or Binimetinib Combined With cMET Inhibitor PF-02341066 in Patients With RAS Mutant and RAS Wild Type (With Aberrant c-MET) Colorectal Cancer
Brief Summary This trial is designed to try two new cancer drugs together for the first time. The investigators think that they might be effective in some types of bowel cancer. The first part of the trial will see what doses of the two drugs can safely be given together. Once the investigators have identified a suitable dose combination they will look at how effective treatment is in bowel cancers where either the RAS gene is mutated, or MET is over-active. In the trial the investigators will look at samples of blood, skin and tumour to check the drugs are working in the way expected. The trial will take place in three sites in the UK and 5 sites in Europe. The trial is funded as part of the European commission's FP7 program.
Detailed Description

This is a two stage study. Firstly a dose escalation step is used to define the best dose for the drug combination, using the rolling 6 design where up to 6 patients are recruited at each dose level, and increasing the dose of one or other agent according to the side effects of treatment. An initial dose escalation phase was completed where 25 patients were enrolled, using the study treatment combination of PD-0325901 with PF-02341066. Following discontinuation of the MEKi (inihibitor), PD-0325901, the study was updated to include a further dose escalation phase using the new combination study treatment, MEKi, Binimetinib with METi, PF-02341066. The effects of this drug combination will be assessed to define the recommended dose level for the dose expansion phase of the study.

Second the new drug combination is observed in 42-98 patients with bowel cancer for its efficacy and tolerability. Patients who give consent will have their archival tumour samples tested for RAS and c-MET status.

Potential participants will, after giving consent, undergo screening tests to ensure that it is safe for them to take part. These involve a detailed medical history, physical exam, blood tests, ophthalmology exam, ECG and ultrasound and skin biopsies. The size and extent of tumours is also assessed by CT and/or MRI scan.

For the initial dose escalation phase, on assurance that the test results are satisfactory, patients start on PD-0325901 first for one week. On Day -7 a physical exam, ECG and blood test is performed, with a repeat blood test on Day -6. End of first week PD samples of blood are taken to observe the level of PD-0325901. Day 1 PF-02341066 is introduced after further clinical safety assessments. There are further blood samples taken over 24 hours to measure levels of PD-0325901 and PF-02341066 on days 21 and 28 of the first cycle.

For the further dose escalation phase, again assuming that the screening test results are satisfactory, patients start on Day 1 with the combined treatment of PF-02341066 with Binimetinib. A physical exam, ECG and blood test is performed, with a repeat blood test on Day 2. There are further blood samples taken over 24 hours to measure levels of Binimetinib and PF-02341066 on day 21of the first cycle.

Patients have weekly visits when side effects are reviewed and a physical examination is performed. On Day 15 a second skin biopsy is taken along with blood tests to assess liver and renal function. At the end of the first 4 weeks cycle, for the initial dose escalation phase, and at end of 8 weeks for the new combination therapy dose escalation phase, an ophthalmology exam is compared with the baseline assessment.

For subsequent cycles in both the initial dose escalation and further dose escalation phases, visits remain weekly and include safety assessments as per Day 1. Blood levels of PD-0325901 or Binimetinib and PF-02341066 are measured on day 21 of even numbered cycles. In addition the tumour size is checked every second cycle, and the study treatment stopped if the tumour continues to grow.

When patients stop taking the study treatment they will be reviewed after 4 weeks for any side effects and have a physical examination and other safety tests performed.

For patients entering the expansion phase of the trial the procedures are similar, except that there is a pre-screening stage where tumour biopsies are required. Patients will have a sample of their tumour assessed, following consent, to determine their RAS and cMET status. This may involve a fresh biopsy. If suitable, the patient will be entered into the screening for the dose expansion phase and a fresh tumour biopsy may be taken if not already done so. The study schedule is the same as for the escalation phase using Binimetinib with PF-02341066. At the end of treatment a further, optional, tumour biopsy may be taken.

After trial participation patients will be offered further care with the trial team or their referring oncology team as appropriate.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Solid Tumor
  • Colorectal Cancer
Intervention  ICMJE
  • Drug: PF-02341066
    PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
    Other Name: Crizotinib
  • Drug: PD-0325901
    PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
    Other Name: No other Intervention name for this drug
  • Drug: Binimetinib
    Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
    Other Name: MEK162
Study Arms  ICMJE
  • Experimental: Dose Escalation Phase Dose 1.
    Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
    Interventions:
    • Drug: PF-02341066
    • Drug: PD-0325901
  • Experimental: Dose Escalation Phase 2.
    Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
    Interventions:
    • Drug: PF-02341066
    • Drug: PD-0325901
  • Experimental: Dose Escalation Phase 3.
    Crizotinib 250mg OD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
    Interventions:
    • Drug: PF-02341066
    • Drug: PD-0325901
  • Experimental: Diose Escalation Phase 4.
    Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
    Interventions:
    • Drug: PF-02341066
    • Drug: PD-0325901
  • Experimental: Dose Escalation Phase 5.
    Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
    Interventions:
    • Drug: PF-02341066
    • Drug: PD-0325901
  • Experimental: Dose Escalation Phase 6.
    Crizotinib 200mg OD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
    Interventions:
    • Drug: PF-02341066
    • Drug: PD-0325901
  • Experimental: Dose Escalation Phase 7
    Binimetinib 30mg BD continuous administration or days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
    Interventions:
    • Drug: PF-02341066
    • Drug: Binimetinib
  • Experimental: Dose Escalation Phase 8
    Binimetinib 45mg BD continuous administration or days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
    Interventions:
    • Drug: PF-02341066
    • Drug: Binimetinib
  • Experimental: Dose Escalation Phase 9
    Binimetinib 45mg BD continuous administration or days 1-21 every 28 days. PF-02341066 250mg BD continuous administration
    Interventions:
    • Drug: PF-02341066
    • Drug: Binimetinib
  • Experimental: Dose Escalation Phase 10
    Binimetinib 30mg BD continuous administration or days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
    Interventions:
    • Drug: PF-02341066
    • Drug: Binimetinib
  • Experimental: Dose Escalation Phase 11
    Binimetinib 45mg BD continuous administration or days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
    Interventions:
    • Drug: PF-02341066
    • Drug: Binimetinib
  • Experimental: Dose Expansion Phase
    PF-02341066 (Crizotinib) 200mg OD/ 200mg BD Days 1-28 continuously Binimetinib 30mg/45mg Dosage to be determined once the recommended Phase II dose has been identified in the dose escalation phase.
    Interventions:
    • Drug: PF-02341066
    • Drug: Binimetinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: November 22, 2018)
82
Original Estimated Enrollment  ICMJE
 (submitted: July 27, 2015)
48
Estimated Study Completion Date  ICMJE September 2019
Estimated Primary Completion Date January 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

INCLUSION CRITERIA (Inclusion criteria for the completed initial dose escalation phase using PF-02341066/PD-0325901 are listed in Appendix 7.) All patients

  • Age ? 16 years (>18 years in France)
  • ECOG performance status 0-1 (Appendix 1)
  • Adequate respiratory function on clinical assessment
  • Left ventricular ejection fraction (LVEF) ? 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram?
  • Able to give informed consent prior to any screening procedures being performed and be capable of complying with the protocol and its requirements
  • Haematological and biochemical indices within the ranges shown below:
  • Haemoglobin (Hb) ? 9g/dl (transfusion to achieve this allowed ),
  • Neutrophils ? 1,500/?l,
  • Platelet count ? 100,000/?l,
  • AST or ALT ? 2.5 x ULN, patient with liver metastases ? 5 × ULN,
  • Alkaline phosphatase ? 5 x ULN,
  • Serum Bilirubin ? 1.5 x ULN,
  • Creatinine Clearance ? 50ml/min (Calculated by Cockcroft Gault equation, or by EDTA) (Appendix 2)
  • Able to swallow oral medication
  • Life expectancy of at least 3 months.

Dose escalation phase:

  • Patients with any advanced solid tumours
  • Patients for whom the combination of PF-02341066 with Binimetinib is a reasonable option.

Dose expansion phase:

Patients will be eligible for pre-screening for this phase provided that:

  • They have given informed consent to screening.
  • They are willing to undergo a biopsy for assessment of tumour RAS mutation status and c-MET assessment.
  • The Investigator anticipates that they are likely to satisfy the eligibility criteria for the trial. Formal screening should not be performed until the tumour pre-screening result is known.

Eligibility for the trial, in patients passing pre-screening, requires:

  • Histologically confirmed colorectal adenocarcinoma that is either a) RASMT (KRAS codon 12, 13, 61, 117, 146; NRAS codon 12, 13, 61, 117, 146) or b) RASWT/c-MET mutated/amplified or c) RASWT/c-MET over-expressed with progressive disease on or within 6 months of completion of adjuvant therapy or after chemotherapy and/or targeted therapies for metastatic disease.
  • Prior treatment with an EGFR targeted monoclonal antibody for patients with RASWT/c-MET mutated or amplified CRC or c) RASWT/c-MET over-expressed CRC.
  • No evidence for a mutation in BRAF at codon600
  • Metastases accessible for biopsy on 2-3 occasions
  • At least one other measurable lesion (according to RECIST v1.1).
  • Unsuitable for potential curative resection. ?For non-UK territories: if echocardiogram (ECHO) cannot be performed, a MUGA scan may be performed in compliance with local policy, applicable national legislation and relevant approvals. Cardiac ejection fraction must be determined as measured by ECHO in the UK.

EXCLUSION CRITERIA (Exclusion criteria for the completed initial dose escalation phase using PF-02341066/PD-0325901 are listed in Appendix 7.) All patients

  • Unstable ischaemic heart disease, cardiac dysrhythmias, coronary/peripheral artery bypass graft or cerebrovascular accident within 6 months prior to starting treatment.
  • Uncontrolled arterial hypertension despite medical treatment.
  • Ongoing congestive heart failure or cardiac dysrhythmias of NCI CTCAE Grade ?2 or uncontrolled atrial fibrillation.
  • History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease (ILD), obliterative bronchiolitis, and pulmonary fibrosis. A history of prior radiation pneumonitis is allowed.
  • Any active central nervous system (CNS) lesion (i.e., those with radiographically unstable, symptomatic lesions) and/or leptomeningeal metastases. However, patients treated with stereotactic radiotherapy or surgery are eligible if the patient remained without evidence of CNS disease progression ? 3 months. Patients must be off corticosteroid therapy for ? 3 weeks.
  • Patients who have neuromuscular disorders that are associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy);
  • Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment. NB: Muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on Binimetinib treatment
  • Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function.
  • Carcinomatous meningitis or leptomeningeal disease.
  • History of hypoalbuminaemia, or patients with peritoneal disease or pleural disease, where there is a requirement for ascitic or pleural taps.
  • History of retinal vein occlusion, intraocular pressure > 21 mmHg or patient considered at risk of retinal vein thrombosis (e.g. history of hyperviscosity or hypercoagulability syndromes).
  • History of retinal degenerative disease.
  • History of Gilbert's syndrome.
  • Active infections (including chronic hepatitis type B or C and HIV infection if status known), severe immunologic defect, compromised bone marrow function.
  • Other severe acute or chronic medical (including severe gastro-intestinal disorders e.g. partial bowel obstruction, malabsorption, active inflammatory bowel disease) or psychiatric conditions or laboratory abnormalities that the investigator considers would make the patient a poor trial candidate, would impart excess risk associated with study participation or drug administration or could interfere with protocol compliance or the interpretation of trial results.
  • Patients who have undergone major surgery ? 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure.
  • Use of drugs or foods that are known potent CYP3A4 inhibitors or inhibitors or are CYP3A4 substrates with narrow therapeutic indices (see Appendix 5).
  • Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C) and four weeks for investigational medicinal products before treatment. Patients with prostate cancer may continue to receive endocrine therapy to maintain castrate levels of androgens.
  • Resting ECG with QTc > 480msec at 2 or more time points within a 24h period (using Fredericia correction).
  • Requirement for medication known to prolong QT interval (Appendix 5).
  • History of other malignancy less than 3 years before the diagnosis of current cancer, EXCLUDING the following: Non-melanoma skin cancer, in situ carcinoma of the cervix treated surgically with curative intent, other malignant tumours that have been treated curatively and patient is deemed disease-free
  • Women with the ability to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum pregnancy test before enrolment and agree to use one highly effective form of contraception (oral, injected or implanted hormonal contraception or intra-uterine device) in addition to condom plus spermicide for four weeks before entering the trial, during the trial and for six months afterwards are considered eligible.
  • Male patients with partners of child-bearing potential unless they agree to take measures not to father children by using one form of highly effective contraception including oral, injected or implanted hormonal contraception or intra-uterine device in addition to condom plus spermicide, during the trial and for six months afterwards). Men with pregnant or lactating partners should be advised to use barrier method contraception (condom plus spermicidal gel) to prevent exposure to the foetus or neonate.
  • Prior exposure to any of a HGF, cMET or a MEK inhibitor.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 16 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02510001
Other Study ID Numbers  ICMJE OCTO-049
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party University of Oxford
Study Sponsor  ICMJE University of Oxford
Collaborators  ICMJE
  • Queen's University, Belfast
  • Oxford University Hospitals NHS Trust
  • Velindre NHS Trust
  • University Hospital, Antwerp
  • Hospital Vall d'Hebron
  • Saint Antoine University Hospital
  • European Georges Pompidou Hospital
  • Pfizer
  • University of Turin, Italy
  • Belfast Health and Social Care Trust
  • Beaumont Hospital
  • European Commission
  • Array BioPharma
  • University of Paris 5 - Rene Descartes
Investigators  ICMJE
Principal Investigator:Mark R MiddletonOxford University Hospital NHS Trust
PRS Account University of Oxford
Verification Date November 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP